close

TOPADUR mentioned in Innosuisse Annual Report 2019

Glaucoma is the second most common cause of blindness after cataracts, with over 100,000 people suffering from glaucoma in Switzerland and over 64 million people worldwide.  With its latest research, TOPADUR, with the support of Innosuisse and in collaboration with the University of Zurich and the Institute for Molecular and Clinical Ophthalmology of the University Hospital Basel, is researching a novel active ingredient that is expected to be on the market by 2026.

Extract from INNOSUISSE ANNUAL REPORT 2019: